cefoperazone-sulbactam + ciprofloxacin

Cefoperazone-sulbactam + ciprofloxacin is a combination therapy consisting of two antibiotics (cefoperazone and ciprofloxacin) and a beta-lactamase inhibitor (sulbactam). Cefoperazone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis. Sulbactam is a beta-lactamase inhibitor that protects cefoperazone from enzymatic degradation by beta-lactamase-producing bacteria, thereby extending its spectrum of activity[8]. Ciprofloxacin is a second-generation fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, enzymes essential for DNA replication[6]. This combination may be used in clinical settings to treat severe or resistant infections caused by susceptible gram-negative and some gram-positive organisms, including multidrug-resistant strains. The rationale for combining these agents includes broadening the antibacterial spectrum, overcoming resistance mechanisms (such as beta-lactamases), and achieving potential synergistic effects against difficult-to-treat pathogens[1][2][8].

Other names

cefoperazone plus sulbactam and ciprofloxacincefoperazone/sulbactam + ciprofloxacin